At a glance
A non-peptide compound involved in mitochondrial fatty-acid transport.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Studies vary by route, baseline status and indication. Oral supplementation results cannot automatically justify an injectable research-vial schedule.[1][2][5]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of L-Carnitine.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 200 mg · 1 source tables
Standard / Gradual Approach (2.0 mL = 100 mg/mL)
| Week | Daily Dose | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 50 mg | 50 units (0.50 mL) |
| Weeks 3–8 | 100 mg | 100 units (1.0 mL) |
| Weeks 9–12 | 100 mg | 100 units (1.0 mL) |
Frequency: Inject once daily subcutaneously. This 2.0 mL reconstitution provides optimal concentration for convenient dosing: 100 mg maintenance dose = exactly 1.0 mL (100 units)[7]. For advanced protocols requiring 150–200 mg daily, doses above 1.0 mL may be split into two injections at different sites to improve comfort.
Additional schedule context & duration
Concise summary of the once-daily subcutaneous regimen.
- Goal: Support mitochondrial fatty acid oxidation and energy metabolism while avoiding TMAO production associated with oral dosing[4].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 50–100 mg daily with gradual titration; advanced protocols may use up to 200 mg daily.
- Reconstitution: 2.0 mL per 200 mg vial (100 mg/mL) for precise 1:1 unit-to-milligram measurement.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw cycles.
Suggested daily titration approach based on clinical literature.
- Start: 50 mg daily for Weeks 1–2 to assess tolerance and monitor for injection-site reactions[7].
- Maintenance: Increase to 100 mg daily from Week 3 onward; this is a reasonable maintenance dose for most research purposes[7].
- Advanced: Up to 200 mg daily for robust experimental protocols, if clearly supported by research findings[7].
- Frequency: Once per day subcutaneously (any consistent time; morning or pre-exercise commonly used).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks with continued monitoring.
- Site Rotation: Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent tissue irritation.
Preparation
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water (0.9% benzyl alcohol) with a sterile syringe.
- Inject slowly down the vial wall to minimize foaming; avoid direct stream onto powder.
- Gently swirl or roll the vial until powder is fully dissolved (do not shake vigorously).
- Label vial with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 2–4 weeks; bacteriostatic water preservative inhibits microbial growth during multi-dose use[6].
Storage Instructions
Proper storage preserves peptide stability and potency.
- Lyophilized (unreconstituted): Store at −20 °C (−4 °F) or below in dry, dark conditions; minimize moisture exposure. Keep vial tightly sealed. Stable for months to years when frozen[11].
- Reconstituted solution: Refrigerate at 2–8 °C (35.6–46.4 °F) immediately after mixing. Do not freeze reconstituted solution as this can degrade the peptide[7].
- Stability timeline: With bacteriostatic water (0.9% benzyl alcohol), reconstituted L-Carnitine remains usable for 2–4 weeks when refrigerated[7][11]. Benzyl alcohol suppresses bacterial growth during multi-dose use[6].
- Before use: Allow refrigerated vials to reach room temperature before opening to reduce condensation. Inspect solution before each use; discard if discolored or contains precipitates.
- Avoid freeze–thaw cycles: Repeated freezing and thawing degrades peptide integrity; aliquot into smaller vials if long-term storage is needed[11].
Materials & quantity planning
Source materials checklist · 200 mg
Plan based on an 8–16 week daily protocol using 100 mg maintenance dose (most common). If starting with 50 mg titration (Weeks 1–2), subtract ~3–4 vials from totals below.
-
Peptide Vials (L-Carnitine, 200 mg each):
- 8 weeks (56 days @ 100 mg/day) ≈ 28 vials
- 12 weeks (84 days @ 100 mg/day) ≈ 42 vials
- 16 weeks (112 days @ 100 mg/day) ≈ 56 vials
Note: Each 200 mg vial reconstituted at 2.0 mL provides two 100 mg doses (or four 50 mg doses).
-
Insulin Syringes (U-100, 1 mL capacity):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- 8 weeks (28 vials): 56 mL → 6 × 10 mL bottles
- 12 weeks (42 vials): 84 mL → 9 × 10 mL bottles
- 16 weeks (56 vials): 112 mL → 12 × 10 mL bottles
-
Alcohol Swabs: One for vial stopper + one for injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
- Sharps Container: For safe disposal of used syringes and needles.
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 200 mg per vial and 2 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
Clinical Nutrition ESPEN (2020) — Talenezhad N et al. Meta-analysis of 37 RCTs: L-carnitine supplementation yields ~1.2 kg weight loss at ~2,000 mg/day oral dosing with diminishing returns above that dose (PMID: 32359762) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Research publication
American Journal of Kidney Diseases (2001) — Brass EP et al. IV L-carnitine (10–40 mg/kg after dialysis, 3×/week for 24 weeks) increased plasma carnitine, reduced fatigue, preserved exercise capacity in hemodialysis patients with excellent safety profile (PMID: 11325685) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Continue exploring
Related topics are not interchangeable compounds or formulations.